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Growth of human tumours depends on the supply of oxygen and nutrients via the surrounding vasculature. Therefore tumour
vasculature is an attractive target for anticancer therapy. Apart from angiogenesis inhibitors that compromise the formation of new
blood vessels, a second class of specific anticancer drugs has been developed. These so-called vascular disrupting agents (VDAs)
target the established tumour vasculature and cause an acute and pronounced shutdown of blood vessels resulting in an almost
complete stop of blood flow, ultimately leading to selective tumour necrosis. As a number of VDAs are now being tested in clinical
studies, we will discuss their mechanism of action and the results obtained in preclinical studies. Also data from clinical studies will be
reviewed and some considerations with regard to the future development are given.
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Tumour-related angiogenesis is essential for tumour growth and
metastases formation. It is a complex process in which vascular
endothelial growth factor (VEGF) produced by tumour cells plays
a predominant role (Ferrara et al, 2003). Binding of VEGF to the
transmembrane endothelial VEGF tyrosine kinase receptors
(VEGFR) type 1 or 2 initiates a cascade of intracellular signaling
pathways resulting in endothelial cell proliferation and the
formation of new blood vessels. Apart from VEGF, basic fibroblast
growth factor, platelet-derived growth factor, interleukin-8 and
insuline-like growth factor are proangiogenic factors. Natural
antiangiogenic factors produced by tumour and host cells are
tumour necrosis factor alpha (TNF-a), serotonin (5-HT), nitric
oxide (NO), thrombospondin, angiostatin and endostatin.
Inhibiting angiogenesis has become a challenge in the develop-
ment of a totally new class of anticancer drugs as was already
acknowledged in 1971 by Folkman (1971). Angiogenesis inhibitors
can be divided into two groups, monoclonal antibodies (Moabs)
and small molecule tyrosine kinase inhibitors (TKIs). Bevacizumab
is a humanised Moab targeting VEGF, which has shown clinical
activity in combination with cytotoxic chemotherapy in metastatic
colorectal cancer, non-small cell lung cancer (NSCLC) and breast
cancer (Hurwitz et al, 2004; Ramaswamy et al, 2006; Sandler et al,
2006). As single agent bevacizumab has demonstrated acivity in
metastatic renal cell carcinoma (Yang et al, 2003).
Apart from Moabs, a large number of small-molecule VEGFR
TKIs have been explored in clinical studies. Results in randomised
studies in renal cell carcinoma with the broadspectrum TKIs
sunitinib and sorafenib have resulted in their regulatory approval
for this disease (Escudier et al 2007; Motzer et al, 2007). Most other
TKIs so far have either only been tested in smaller phase I and II
studies, or have failed to show meaningful effects in larger
randomised phase III studies (Koehne et al, 2006). Theoretically, it
is conceivable that angiogenesis inhibitors will exert optimal
activity in a situation of minimal residual disease with high-
angiogenic potency such as could be the case in the adjuvant
setting.
Although inhibiting angiogenesis thus seems to be successful in
various conditions, an urgent need for more optimal treatment
options in metastatic disease exists.
For example, what to do with the already established tumour-
related vasculature?
Vascular targeting strategies can be divided into two different
approaches: as mentioned above an antiangiogenic approach, but
apart from that a so-called vascular disrupting approach has
emerged (Siemann et al, 2005). Vascular disrupting agents (VDAs)
target endothelial cells and pericytes of the already established
tumour vasculature. Although this approach looks very interesting
from a theoretical point of view, one of the critical issues one could
raise is that of tumour specificity; do VDAs selectively target
tumour-related endothelium or is there a more general vascular
targeting effect with a risk of subsequent ischaemic complications?
In the following sections we will discuss in more detail the
hypothesised mechanisms of action of VDAs and will review
results of preclinical and clinical studies performed so far. Finally,
we will give some thoughts on were to go with VDAs in future
studies.
VDAs AND THEIR TARGET
Indirect killing of tumours by compromising their vascularisation
is a potentially attractive anticancer treatment approach. On the
one hand drug resistance is not likely to appear because the
targeted endothelial cell has much greater genetic stability than
neoplastic cells (Kerbel and Folkman, 2002). Also drug delivery is
likely to be without compromise, as the endothelium of the tumour
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shutdown is likely to result in a massive ‘downstream’ tumour cell
killing.
Selective vascular shutdown suggests a structural difference in
endothelium of tumour vessels compared to that of normal vessels.
Indeed, tumour vasculature is, among others, marked by a high
rate of endothelial cell proliferation, the absence of pericytes,
abnormalities in the basement membrane and often an increased
vascular permeability. Structurally, disorganised, tortuous, thin-
walled vessels are seen that lack smooth muscle and pericyte coats
and innervation (Figure 1) (Kakolyris et al, 2000; Konerding et al,
2001). Blood flow frequently is sluggish and at times might be
stationary or even in a reversed direction (Tozer et al, 1990).
Vessel diameters are irregular and lengths between branches are
long, resulting in a high resistance to blood flow. A small decrease
in perfusion pressure, which has little effect in normal tissue,
therefore can be catastrophic to tumours.
Finally, endothelial cells are highly dependent on tubulin
cytoskeleton for their motility, invasion, attachment, alignment
and proliferation (Denekamp, 1982).
Most VDAs induce changes in endothelial cell shape by
disruption of the cytoskeleton and cell-to-cell junctions. This
results in increased permeability to proteins and an increased
interstitial fluid pressure, which might be sufficient to reduce
vessel diameter. Plasma leakage also leads to increased blood
viscosity resulting in decreased blood flow and roulaux formation.
Another factor contributing to the vascular shutdown is the
activation of platelets through contact with basement membrane
components, which are exposed. All together this cascade of events
results in vascular shutdown more selectively in tumour endo-
thelium than normal endothelium. As stated previously, it is
suggested that the inhibition of blood flow and the subsequent
compromised supply of oxygen and nutrients will induce necrosis
of many tumour cells downstream.
Compared to the antiangiogenic approach of both TKI and
Moab, the vascular disrupting approach therefore seems to be
cytotoxic rather than cytostatic. However, in preclinical models
it has been observed that following exposure to a VDA, only the
centre of a tumour becomes necrotic, with a viable rim (Figure 2)
remaining in the periphery. This rim of viable tumour cells
presumably survives because it derives nutritional support (most
likely via diffusion) from adjacent normal blood vessels that are
typically less responsive to VDAs.
To demonstrate biological activity of VDAs in preclinical and
clinical studies, noninvasive techniques such as dynamic contrast-
enhanced magnetic resonance imaging (DCE–MRI) and positron
emission tomography scans (PET) have been explored. This type
of imaging can demonstrate changes in tumour perfusion and
tumour viability (Beauregard et al, 1998; Galbraith et al, 2003).
Although data to date look very promising, one must realise that
both techniques are not yet validated to predict antitumour
activity or real patient benefit in the clinical situation.
VDAs IN CLINICAL DEVELOPMENT
Vascular disrupting agents have been divided into two types, small
molecule and ligand directed VDAs. We will focus on small
molecule VDAs because they are in a more advanced stage of
clinical development. Small molecule VDAs can be divided into
two groups; the tubulin-binding agents and the flavonoids. Their
mechanism of action is somewhat different as will be discussed.
Tubulin-binding agents are combretastatin, AVE8062, ZD6126,
ABT-571, MN-029 and the dolatastatin derivative TZT-1027. Of the
flavonoids only 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
will be discussed.
I. TUBULIN-BINDING AGENTS
These agents work by acting at the colchicines-binding site of the
b-subunit of endothelial tubulin, resulting in depolymerisation of
microtubules and disorganisation of actin and tubulin. Disruption
of the endothelial cytoskeleton results in conformational changes
leading to loss of blood flow. In addition to this, a recent study
showed that the typical microtubule-destabilising agent com-
bretastatin A4 phosphate (CA4P) also selectively disrupts the
VE-cadherin/b-catenin complex interfering with cell–cell contact
(Vincent et al, 2005). Loss of this cell–cell contact increases
vascular permeability leading to increased interstitial pressure and
additional loss of blood flow. In addition to these effects, the
already mentioned loss of cell–cell contact results in the exposure
of the already often abnormal basement membrane, which in turn
can result in the induction of the coagulation cascade with
subsequent thrombus formation. Tumour-related endothelial cells
are much more sensitive to the activity of tubulin-binding agents
than normal endothelial cells (Chaplin and Dougherty, 1999).
Combretastatin A4 phosphate
Combretastatin A4 phosphate is a water-soluble prodrug of
combretastatin A4 (CA4). Following administration, CA4P is
rapidly cleaved to CA4 and binds tubulin at or close to the
colchicines-binding site (McGown and Fox, 1989). One of the first
in vivo studies showed rapid, extensive and irreversible vascular
shutdown and haemorrhaghic necrosis following a single dose of
CA4P. A pronounced and sustained reduction in functional
Figure 1 Architectural difference between vasculature in normal (small
arrows) and tumour tissue (thick arrows).
Figure 2 Typical example of a tumour with a viable rim (V) and central
necrosis (N) following exposure to a vascular disrupting agent.
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dose much lower than the maximum-tolerated dose (MTD) (Dark
et al, 1997). Histological as well as DCE–MRI studies in preclinical
models show that the antivascular effects of CA4 are restricted to
the core of the tumour, leaving viable tumour cells at the periphery
(Beauregard et al, 1998). Combretastatin A4 shows different
activity in normal and tumour endothelium in preclinical models;
Tozer et al (1999) showed a 100-fold decrease in blood flow in p22
carcinosarcomas with a much smaller reduction in blood flow in
the spleen, skeletal muscle and brain. No significant reduction in
blood flow was seen in heart, kidney and intestine.
Three phase-I trials of CA4P in humans have been published
(Table 1). In the first study by Rustin et al (2003a) CA4P was given
weekly for 3 weeks followed by a week gap . Thirty-four patients
with advanced solid tumours received 167 infusions. Up to
40mgm
 2, the only drug-related toxicity was tumour pain in
35%. Tumour pain was not considered a dose-limiting toxicity
(DLT) because it could be controlled by analgesics. Tumour
viability and tumour blood flow were assessed by PET and
DCE–MRI (Galbraith et al, 2003). Dose-limiting toxicity were fatal
ischaemia in previously irradiated bowel, vasovagal syncope,
motor neuropathy and reversible ataxia. Other side-effects were
hypertension (35%), hypotension (30%), tachycardia (53%),
bradycardia (24%), nausea (21%), fatigue (23%), visual distur-
bance (9%) and dyspnoea (6%). The drug was generally well
tolerated and no myelosuppression, alopecia and mucositis were
seen. One partial response was seen (metastatic adrenocortical
carcinoma). The recommended phase-II dose of 52–68mgm
 2
was based upon clinical tolerability and the assessment of
biological activity by means of PET and DCE–MRI analysis.
In a second phase-I study, Stevenson et al (2003) used a daily
infusion for 5 days every 3 weeks . Thirty-seven patients received
133 cycles. Dose-limiting toxicities were tumour pain, reversible
sensorimotor neuropathy, syncope and dyspnoea. No cardiotoxi-
city or electrocardiographic changes were seen. One patient with
metastatic sarcoma had a partial response, and 14 patients showed
stable disease. The recommended phase-II dose was 52mgm
 2.
Dowlati et al (2002) used a once every 3 weeks schedule.
Twenty-five patients received 107 cycles. Dose-limiting toxicities
were cardiac ischaemia and dyspnoea in two patients with pre-
existing cardiovascular disease. A significant decline in gradient
peak tumour blood flow by DCE–MRI was observed in six patients
treated at 60mgm
 2. One complete response was observed in a
patient with anaplastic thyroid cancer, whereas two patients
experienced freedom from disease progression lasting more than
12 months. Dosages up to 60mgm
 2 as a 10-min infusion defined
the upper boundary of the MTD. Cooney et al (2004) determined
the cardiovascular safety profile of CA4P in the same patient
cohort. They observed asymptomatic QTc prolongation as DLT.
Apart from this, two patients had an acute coronary syndrome
within 24h after the infusion of CA4P .
All mentioned studies used a different dosing schedule (weekly,
3-weekly, daily for 5 days every 3 weeks) and showed that CA4P
was safe, well tolerated and lacking haematologic toxicity. In all
studies MTDs of 50–60mgm
 2 were set with consistent indica-
tions of antivascular effects observed by either DCE–MRI or PET.
Currently CA4P is further explored as single agent in phase-II
studies in patients with advanced anaplastic thyroid cancer.
Apart from single-agent approaches, CA4P has been studied in
combination with carboplatin. Combretastatin A4 was given 3-
weekly (27–36mgm
 2) 60min after carboplatin (AUC 4–5).
Dose-limiting toxicity was trombocytopenia (Bilenker et al, 2005).
In another ongoing study, induction chemotherapy using
doxorubicin and cisplatin is followed by CA4P and radiation
therapy in patients with newly diagnosed advanced anaplastic
thyroid cancer.
Finally, CA4P is currently being explored in combination with
carboplatin and paclitaxel in patients with advanced solid
tumours.
AVE8062
AVE8062 is a water-soluble analogue of CA4 with markedly
enhanced antitumour effects. Preclinical studies have shown rapid
and irreversible vascular shutdown in various different orthotopic
tumour models. Complete stasis of blood flow was observed after
30min, whereas blood flow in normal tissues was compromised
but returned to pretreatment levels within 24h. Tumour cell
proliferation in different models was suppressed after drug
infusion (Hori et al, 2002). So far only one phase-I single-agent
study has been published in which nine patients received 48
infusions of AVE8062 (Table 1) (Tolcher et al, 2003). Cardiovas-
cular effects consisting of asymptomatic systolic hypotension
without elevation of CPK or troponin I levels or ECG changes were
observed. Decreased tumour blood flow was observed by DCE–
MRI at the 15.5mgm
 2 dose level. The half-life of AVE8062 was
15min, but an active metabolite was formed with a half-life of 7h.
No response data are available. Currently, single-agent phase-I
studies exploring other schedules of administration are ongoing.
Table 1 Currently published phase-I studies
Drug Company Treatment schedule Dose range DLT
a References
CA4P OXiGEN d 1,8,15 q4w
d 1–5 q3w
d 1 q3w
5–114mgm
 2 i.v.
6–75mgm
 2 i.v.
18–90mgm
 2 i.v.
Bowel ischaemia, tumour pain, vagal syncope,
motor neuropathy, reversible ataxia, cardiac
ischaemia, dyspnoe
Rustin et al
Stevenson et al
Dowlati and Cooney et al
AVE8062 Sanofi Aventis d 1,8,15 q 4 4.5–40mgm
 2 i.v. Transient myocardial ischaemia, asymp
hypotension, transient neurological symptoms
Tolcher et al
ZD6126 Astra Zeneca weekly
d 1 q3w
d 1 q3w
5–28mgm
 2 i.v.
5–40mgm
 2 i.v.
5–112mgm
 2 i.v.
Myocardial infarction, pulm. embolus, LVEF
decrease, fatigue
Beerepoot et al
LoRusso et al
Gadgeel et al
ABT-751 Abbott q.d. 7 days q3w
b.i.d 7 days q3w
200–300mg po
125–175mg po
Ileus, constipation, abdominal pain, neuropathy,
fatigue
Hande et al
MN-029 MediciNova 3-weekly 4–180mgm
 2 i.v. Reversible cardiac ischaemia Ricart et al
TZT- 1027 Daichi
Pharmaceuticals
d 1,8 q3w
d1,8 q3w+carbo AUC 4–5
d 1 q3w
1.35–2.7mgm
 2 i.v.
1.6–2.0mgm
 2 i.v.
1.35–3.0mgm
 2 i.v.
Neutropenia, pain infusion arm, peripheral
neuropathy
fatigue, ileus
de Jonge et al
Greystoke et al
Schoffski et al
DMXAA Antisoma Weekly
d 1 q3w
6–4900mgm
 2 i.v.
6–4900mgm
 2 i.v.
Reversible urinary incontinence, visual
disturbances, anxiety
Rustin et al
Jameson et al
DLT¼dose-limiting toxicity; i.v.¼intravenously. Ref. ¼References.
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with oxaliplatin and docetaxel (Demers et al, 2006), clinical studies
exploring these combinations are currently also ongoing.
ZD6126
In preclinical models this agent demonstrated significant anti-
tumour activity. Stasis of blood flow was seen at doses 1/8–1/16 of
the MTD and occurred specifically in tumour tissue (Davis et al,
2002). Two phase-I studies, in which ZD6126 was given thrice
weekly, have been presented (Gadgeel et al, 2002; LoRusso et al,
2002) (Table 1). One patient showed asymptomatic, reversible
cardiac ischaemia with subsequent demonstration of coronary
artery disease. Maximum-tolerated dose was set at 112mgm
 2,
whereas biological activity indicated by a sustained decrease in
tumour blood flow measured by DCE–MRI occurred at doses
above 80mgm
 2. A third phase-I study has recently been
published (Beerepoot et al, 2006). Here, ZD6126 was given weekly
to 32 patients. Dose-limiting toxicity consisted of myocardial
infarction and was observed at a dose of 10mgm
 2 in one patient.
This patient was found to have a history of ischaemic heart disease.
Two patients treated at 28mgm
 2 experienced DLT, one each with
pulmonary embolus (disease-related?) and asymptomatic decrease
in left ventricular ejection fraction. Maximum-tolerated dose was
set at 20mgm
 2. In all three studies ZD6126 was well tolerated and
only showed mild side effects such as anaemia, nausea, vomiting
and constipation. So far no objective tumour responses have been
observed. Currently, ZD6126 is being explored in metastatic renal-
cell carcinoma.
ABT-751
ABT-751 is a sulphonamide molecule that can be given orally, and
has shown significant antitumour activity in a variety of tumour
models (Ozawa et al, 2001). In a phase-I study, 39 patients with
solid tumours were given ABT-751 once or twice daily for 7 days
every 3 weeks (Table 1) (Hande et al, 2006). Dose-limiting
toxicities were ileus and neuropathy at 300mg daily. In the twice
daily schedule, grade 3 ileus, constipation, abdominal pain and
fatigue were observed. One minor response and four patients with
stable disease lasting for 6 months were observed. The MTD and
recommended phase-II doses for ABT-751 were 250mg daily and
150mg twice daily for 7 days every 3 weeks. Phase I/II studies are
currently ongoing, evaluating the safety and efficacy of ABT-751 in
combination with pemetrexed or docetaxel in patients with
NSCLC.
MN-029
One preclinical study was published using a rodent KHT sarcoma
model. After intraperitoneal injection of 100mgkg
 1 a significant
reduction in the functional vessel number was seen. Treatment
with MN-029 resulted in dose-dependent tumour cell killing.
Effects were enhanced by combining the agent with radiation and
cisplatin chemotherapy (Shi and Siemann, 2005). Only one
ongoing phase-I study has been reported so far (Table 1). In this
study, 28 patients with various solid tumours recieved 110 cycles.
Dose-limiting toxicity consisted of reversible cardiac ischaemia at
180mgm
 2. Seven patients had stable disease after 3 cycles.
Dynamic contrast-enhanced magnetic resonance imaging analysis
indicated significant dose-dependent reductions in tumour blood
flow. Accrual at 225mgm
 2 continues (Ricart et al, 2006).
TZT-1027
TZT-1027 is a synthetic derivative of dolastatin-10 with cytotoxic
and antivascular activity. Three different treatment schedules have
been explored in phase-I trials (Table 1). Schoffski et al (2004)
performed a phase-I study in which 21 patients received TZT-1027
infusions at 3-weekly intervals. Dose-limiting toxicities were
neutropenia, fatigue and short lasting peripheral neuropathy.
Anorexia, alopecia and constipation were also seen. The recom-
mended phase-II dose was set at 2.7mgm
 2. A second phase-I
study, exploring day 1 and 8 every 3 weeks administration in 17
patients showed comparable DLTs as well as pain in the infusion
arm lasting 1–2 days at a dose of 2.7mgm
 2 (DeJonge et al, 2005).
Other side effects included nausea, fatigue, vomiting and
diarrhoea. One patient with metastatic liposarcoma had an
ongoing partial response for more than 54 weeks. The recom-
mended dose for phase-II studies of TZT-1027 in this study was set
at 2.4mgm
 2. A third phase-I study explored the combination of
TZT-1027 with carboplatin in 14 patients (Greystoke et al, 2006).
Dose-limiting toxicity consisted of neutropenia and grade 3 ileus.
Other toxicities were comparable to those mentioned above. No
pharmacokinetic interaction between carboplatin and TZT-1027
was observed. One patient with metastatic adenocarcinoma of
the pancreas showed a partial response lasting 181 days. The
recommended phase-II doses of TZT-1027 in combination with
carboplatin AUC 5 was set at 1.6mgm
 2.
II. FLAVONOIDS
DMXAA
5,6-Dimethylxanthenone-4-acetic acid is an active analogue of
flavone acetic acid causing DNA damage to endothelial cells that
induces apoptosis in preclinical models (Corbett et al, 1986). In
response to vascular damage 5-HT is released by platelets that
further enhances the vascular effects (Baguley et al, 1997).
Although the exact mechanism of action of DMXAA is unknown,
its activity involves pathways leading to upregulation of the
nuclear transcription factor NfkB, which leads to production of
TNF-a and other cytokines (Ching et al, 2002). Tumour blood flow
decreases and 5-HT levels increase. In addition, NO is produced in
response to DMXAA, improving blood flow and vascular perme-
ability, increasing the effects of TNF-a and 5-HT (Thomsen et al,
1991). How these forces oppose each other is unknown.
Two phase-I trials have been published so far (Table 1). Rustin
et al (2003b) treated 46 patients with weekly infusions and
documented rapidly reversible DLTs like urinary incontinence,
visual disturbance (blurring, colour disturbance and photophobia)
and anxiety. No tumour pain was seen. Maximum-tolerated dose
was set at 3700mgm
 2. At dose levels of 650mgm
 2 and above a
dose-dependent increase of 5-HT concentrations in plasma was
seen. There was one unconfirmed partial response at 1300mgm
 2.
In a second study, in which 63 patients received 3-weekly
infusions, comparable DLTs were observed with additional
confusion, slurred speech, tremor and possible left ventricular
failure (Jameson et al, 2003). Asymptomatic transient QTc-
prolongation was seen in 13 patients at high doses. One partial
response was seen in a patient with cervical carcinoma. Maximum-
tolerated dose was set at 3700mgm
 2.
Two randomised phase-II studies combining DMXAA with
conventional chemotherapeutics have recently been published.
Gabra, (2006) randomised 55 patients with recurrent ovarian
cancer to receive paclitaxel (175mgm
 2), carboplatin (AUC 6) and
DMXAA (1200mgm
 2). Preliminary data revealed no additional
toxicity owing to the addition of DMXAA. Efficacy assessments are
pending. In 78 patients with NSCLC, McKeage (2006) also found
no additional toxicity when carboplatin and paclitaxel were
combined with DMXAA. Initial response data suggest additional
benefit from triple treatment compared to conventional therapy
Currently, the efficacy and safety of DMXAA in combination with
docetaxel is assessed in a phase-II study in patients with hormone
refractory metastatic prostate cancer.
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Vascular disrupting agents are a new class of antivascular
anticancer agents that are currently undergoing clinical studies.
At this moment, mainly (ongoing) phase-I studies have been
presented, although some compounds have already entered
phase-II testing either as single agent or in combination with
chemotherapeutics. Therefore, the real (added) value in terms of
patient benefit cannot be fully assessed yet.
What distinguishes VDAs from other vascular targeting agents,
how can we optimally assess their biological and clinical activity
and how should these agents be taken forward?
When assessing the toxicity pattern observed so far in the
various clinical studies described, it is obvious that with regard
to mechanism of action tumour specificity is most likely to be
of critical importance. Vascular disrupting agents disrupt the
established abnormal tumour vasculature by targeting the
immature dysmorphic endothelial cells. As mentioned earlier
tumour endothelium is more vulnerable to the activity of VDAs,
and therefore in the end selective tumour vascular shutdown is
likely to occur. However, based upon the pattern of side effects
observed in clinical studies, normal vascular endothelium seems to
be affected by VDAs as well. Cardiac ischaemia and cardiac
arrhythmias as well as reversible neurologic complications (the
latter not with all agents) seem to underscore this issue and
probably will remain dose limiting in future studies. Of critical
importance therefore will be the assessment of biological activity at
doses that can be administered safely. This will probably mean that
in the design of early clinical studies the concept of looking for
MTD will have to be replaced by the concept of looking for optimal
biological dose, hereby assuming that the therapeutic window of
these agents will permit us to do so. At this moment the probable
optimal way to assess biologic or antivascular activity of VDAs is
by repeated dynamic scanning, and therefore the role of DCE–MRI
and PET analysis must be validated further. Vascular shutdown
and decreased tumour blood flow as an indication of biological
activity have meanwhile been demonstrated by DCE–MRI and/or
PET analysis, whereas the occurrence of tumour pain following
administration of several compounds also can be considered as an
indication of biological and perhaps clinical activity. Whether
biological activity will result in tumour size reduction and
meaningful patient benefit has to be evaluated further in phase
II and randomised phase-III studies. The assessment of cardiac
and neurological complications that can occur in these studies
necessitates optimal communication between oncologists and
other specialists, and this will also be important when patients
willing to be enrolled in studies are being screened (Heeckeren
van, 2006). This is, as we think, a nice example of the tremendous
practical consequences the introduction of a new class of
anticancer drugs could and even should have.
When looking at the observed biological effects induced by
VDAs, the induction of central tumour necrosis whereas leaving a
viable rim at the periphery seems to be a consistent finding.
Probably, this means that there is a rationale to combine VDAs
with other treatment strategies. Many theoretical combinations can
be thought of, and combining VDAs with conventional cytotoxic
treatment is already being pursued to a rather large extent. Apart
from this, the addition of an angiogenesis inhibiting agent
following VDA administration conceivably could induce ‘syner-
gistic’ antiangiogenic activity leading to a complete growth
inhibition and a subsequent state of dormancy of the ‘centrally
killed’ tumour mass. This observation has meanwhile indeed been
made in preclinical models (Siemann and Shi, 2004). In addition,
the combination of low-dose chemotherapy following the admin-
istration of a VDA could also be considered. Here one could think
of the concept of metronomic chemotherapy.
Exploring a combination of VDAs and epidermal growth factor
receptor (EGFR) inhibitors theoretically could also be an interest-
ing approach; here one could speculate that tumour cells in the
viable rim will become apoptotic and die when being deprived of
their growth-stimulating factors such as EGF.
Effectiveness of combination therapies often depends on the
sequence of administration. First increasing the vascular perme-
ability (within minutes) allowing accumulation of a cytotoxic agent
in the tumour and then inducing a shutdown of blood flow (within
hours) could probably kill large amounts of tumour cells. However,
as certain chemotherapeutics have their own vascular side effects
(arterial thrombosis following administration of cisplatin), the
alternative sequence of first administering the VDA followed by
the administration of a cytotoxic drug could also be considered.
Irrespective of the sequence administered, these combination
therapies should be carefully chosen and closely monitored.
From a theoretical perspective, radiation therapy probably must
precede VDA administration because optimal blood flow and oxygen
radical formation might be necessary for an optimal synergistic
effect. Preclinical models have meanwhile shown such a synergistic
effect. Finally, and considered as a very specific example, in tumours
of the extremities, one could think of isolated limb perfusion with
VDAs after clamping; Biologically active concentrations of VDAs
could probably be achieved with only limited systemic exposure,
thus leading to optimal and selective tumour cell killing while
preserving the heart, central nervous system and other potential
organs at risk. Monitoring antivascular effects with either angio-
graphy, DCE–MRI or PET would be challenging.
In conclusion, VDAs are a new and promising class of targeted
anticancer agents. Although their safety currently is the major
focus of research, results that will show anticancer activity are
likely to follow soon.
Their unique mechanism of action merits thorough and
extensive exploration, both as single agent as well as in
combination with other treatment modalities. If these studies are
performed adequately, with a close observation of toxicity, it is to
be expected that in the years to come a clear picture of their role in
anticancer treatment can be established.
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